Crispr Therapeutics (NASDAQ:CRSP) had its price target lifted by Oppenheimer from $65.00 to $80.00 in a research note issued to investors on Monday, November 25th, The Fly reports. The brokerage currently has an outperform rating on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2019 earnings at $0.59 EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
Other analysts have also issued reports about the company. Needham & Company LLC reissued a buy rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a report on Wednesday, July 31st. ValuEngine upgraded Crispr Therapeutics from a sell rating to a hold rating in a report on Friday, November 1st. Zacks Investment Research lowered Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, Goldman Sachs Group lifted their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a neutral rating in a report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $69.54.
Shares of NASDAQ:CRSP traded down $0.25 during midday trading on Monday, reaching $65.14. The company had a trading volume of 883,031 shares, compared to its average volume of 713,580. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a market capitalization of $3.64 billion, a P/E ratio of -18.94 and a beta of 3.30. The stock’s fifty day moving average price is $61.44 and its 200-day moving average price is $49.16.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth approximately $4,366,000. Orbimed Advisors LLC acquired a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $21,167,000. Granahan Investment Management Inc. MA increased its stake in shares of Crispr Therapeutics by 8.3% during the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after acquiring an additional 2,655 shares during the period. Barclays PLC raised its holdings in Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in Crispr Therapeutics by 18.0% during the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after purchasing an additional 1,491 shares in the last quarter. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Gross Domestic Product (GDP)
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.